How AI Is Personalizing Insulin Therapy for Diabetes Patients

Artificial intelligence is increasingly playing a role in healthcare, especially in the diabetes management space. The latest example of this comes from Petah Tikva, Israel-based DreMed Diabetes and Mountain View, CA-based Glooko.  FDA has granted a de novo request for the DreaMed Advisor Pro, an AI-based diabetes treatment decision support software intended to help healthcare providers manage people with Type I diabetes who use insulin pumps and continuous glucose monitoring (CGM). DreaMed Advisor Pro is a cloud-based digital solution generating insulin designed to generate insulin delivery recommendations by analyzing information from CGM, self-monitoring blood glucose, and insulin pump data. DreaMed said the technology applies event-driven learning to refine its understanding for each individual and sends recommendations to the provider on how to optimize a patient's insulin pump settings for basal rate, carbohydrate ratio, and correction factor. “This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their Type I diabetes patients,” said DreaMed CEO Eran Atlas. “Type I diabetes, managed with greater attention, leads to improved patient quality of life and reduced payer health-related costs. Advisor Pro enables patients using CGM and an insulin pump to analyze data and recommend to their provider when a change in diabetes-car...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news